A phase I study of ITM-52
Latest Information Update: 18 Dec 2023
Price :
$35 *
At a glance
- Drugs ITM 52 (Primary)
- Indications Non-small cell lung cancer; Ovarian cancer
- Focus Adverse reactions
- 18 Dec 2023 New trial record
Latest Information Update: 18 Dec 2023